425: OSR Holdings Completes Business Combination with Bellevue Life Sciences Acquisition Corp., Begins Trading on Nasdaq

Bellevue Life Sciences Acquisition Corp. (BLAC) finalizes its business combination with OSR Holdings Co., Ltd., changing its name to OSR Holdings, Inc. and preparing to trade on the Nasdaq.

Summary

• Bellevue Life Sciences Acquisition Corp. (BLAC) held a special meeting on February 13, 2025, where stockholders approved the business combination with OSR Holdings Co., Ltd.
• The company has filed an Amended and Restated Certificate of Incorporation and changed its name to OSR Holdings, Inc.
• Trading on the Nasdaq Stock Market LLC is expected to begin on February 18, 2025, under the ticker symbols OSRH and OSRHW for common stock and warrants, respectively.
• In connection with the Special Meeting, 57,821 shares of BLAC Common Stock were tendered for redemption.
• OSR Holdings will own approximately 67% of the outstanding stock of OSR Holdings Co., Ltd. (OSR).
• OSR stockholders holding an additional 22% of the outstanding OSR shares have agreements for OSR Holdings to acquire their shares via put/call provisions starting in 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The business combination has been completed, and management expresses enthusiasm. However, the redemption of shares and the need for regulatory approval introduce some uncertainty.

Positives

• The business combination is expected to provide OSR Holdings with opportunities to advance and grow its subsidiaries and drug pipelines.
• Management expresses enthusiasm about the transaction and its potential to create long-term value for stakeholders.
• OSR Holdings will continue its business operations in the US, Europe, and South Korea.
• The company has a portfolio of subsidiaries in promising areas such as immunotherapies, disease-modifying therapies, and medical device distribution.

Negatives

• 57,821 shares of BLAC Common Stock were tendered for redemption, which could indicate some shareholder uncertainty.

Risks

• The closing of the transaction is contingent upon receiving foreign investment approval from the Industrial Bank of Korea.
• The company's future performance is subject to various risks and uncertainties, including regulatory approvals, market conditions, and competition.
• The company may require additional financing to sustain its operations.

Future Outlook

OSR Holdings aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions, with ongoing business operations in the US, Europe, and South Korea.

Management Comments

• 'The closing will mark a significant achievement and step forward while remaining true to our foundational business strategy as a global Hub-and-Spoke group of healthcare companies,' stated Kuk Hyoun Hwang, President and CEO of OSR Holdings.
• Sang Hoon Kim, CEO of OSR, said, 'We look forward to executing on our corporate strategy to create long-term value to our subsidiary founders, shareholders and investors, and our employees.'

Industry Context

This announcement reflects the ongoing trend of SPAC mergers in the biotech and healthcare sectors, where companies seek to accelerate their access to public markets and capital for research and development.

Comparison to Industry Standards

• The structure of the business combination, with OSR Holdings owning 67% of OSR and plans to acquire an additional 22% through put/call options, is a fairly standard approach in SPAC transactions.
• Comparable companies that have pursued similar strategies include [hypothetical company 1] and [hypothetical company 2], which also focused on acquiring and operating a portfolio of healthcare-related companies.
• The redemption rate of 57,821 shares will need to be compared to industry averages for SPAC mergers to assess investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders will see their shares converted to OSR Holdings, Inc. and traded on Nasdaq.
• Employees of OSR Holdings Co., Ltd. and its subsidiaries may experience changes as the company integrates with OSR Holdings, Inc.
• Customers and partners of OSR Holdings Co., Ltd. can expect continued business operations and potential expansion of services.
• Investors may see new opportunities for investment in the combined company.

Next Steps

• Receipt of foreign investment approval from the Industrial Bank of Korea.
• Closing of the business combination transaction.
• Commencement of trading on the Nasdaq Stock Market LLC under the ticker symbols OSRH and OSRHW on February 18, 2025.
• Execution of corporate strategy to grow subsidiaries and drug pipelines.
• Potential acquisition of additional OSR shares via put/call provisions commencing in 2026.

Key Dates

Keywords

business combination, OSR Holdings, Bellevue Life Sciences Acquisition Corp, Nasdaq, merger, healthcare, biotech, redemption